A Chinese medicinal composition of Astragalus for treating coronary heart disease and its application

Abstract

The invention discloses an astragalus Chinese medicine composition for treating coronary heart disease and its application. The Chinese medicine composition is composed of 144g of astragalus, 108g of kudzu root, 108g of cassia seed, 108g of tuckahoe, 48g of mistletoe, 36g of chuanxiong and 48g of notoginseng. The Chinese medicine of the present application is aimed at the etiology and pathogenesis of qi deficiency and blood stasis and phlegm turbidity blocking type coronary heart disease at the same time. The Chinese medicine composition has the effects of improving blood circulation, regulating blood lipids and preventing blood stasis through multi-level and multi-faceted conditioning. It is particularly suitable for coronary heart disease patients with multiple complex symptoms such as hyperlipidemia, heart vessel obstruction, phlegm dampness obstruction, etc. At the same time, in the Chinese medicine composition of the present invention, the ministerial drugs kudzu root, cassia seed and tuckahoe have synergistic effects.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and in particular to an astragalus Chinese medicine composition for treating coronary heart disease and application thereof. Background Art

[0002] Coronary heart disease, also known as coronary artery atherosclerosis (CAD), refers to a type of heart disease caused by atherosclerotic lesions in the coronary arteries (arteries that supply blood to the heart), which causes vascular stenosis or blockage, leading to myocardial ischemia, hypoxia or necrosis. Coronary heart disease is one of the most common cardiovascular diseases worldwide and an important cause of death and disability.

[0003] The main cause of coronary heart disease is atherosclerosis of the coronary arteries. Atherosclerosis is a chronic inflammatory disease, and its formation is associated with a variety of risk factors, including: high blood lipids: especially elevated low-density lipoprotein cholesterol (LDL-C), which is the main cause of atherosclerosis; high blood pressure: increases the workload of the heart and promotes the development of atherosclerosis; diabetes: closely related to coronary heart disease, because high blood sugar levels can damage the vascular endothelium and increase the risk of atherosclerosis; obesity and unhealthy lifestyles: including unhealthy diets and lack of exercise, can increase the risk of coronary heart disease.

[0004] In traditional Chinese medicine theory, coronary heart disease is often classified as "chest pain" and "heart pain". Its etiology and pathogenesis mainly involve qi stagnation, blood stasis, phlegm obstruction, cold stagnation, qi deficiency, and yang deficiency. The specific analysis is as follows: qi stagnation and blood stasis: emotional distress, long-term illness and fatigue lead to poor qi movement, and long-term qi stagnation leads to blood stasis, which blocks the collaterals and causes chest pain and heart pain; phlegm turbidity obstruction: improper diet, spleen deficiency and poor transportation and transformation, endogenous phlegm and dampness, phlegm turbidity blocking the heart meridian, heart meridian obstruction and pain; cold stagnation of the heart meridian: cold seasons are prone to coronary heart disease. Traditional Chinese medicine believes that cold evil stagnates the blood, causing heart meridian obstruction, chest tightness and heart pain; qi deficiency and yang deficiency: physical weakness and long-term illness, or old age with insufficient kidney yang, yang deficiency leads to weak heart yang, heart meridian malnutrition, weakened heart function, heart pain, shortness of breath and other symptoms.

[0005] The patent application of prior art CN 115282195A discloses a composition of raw materials for this invention comprising 144g of Astragalus, 108g of Pueraria, 108g of Salvia miltiorrhiza, 48g of Viscum, 108g of Crataegus, 36g of Ligusticum chuanxiong and 48g of Notoginseng. This Chinese medicine composition has the effects of invigorating Qi and activating blood circulation, promoting blood circulation and invigorating kidney. It is mainly used for patients with coronary heart disease and angina pectoris manifested as Qi deficiency, blood stasis and kidney deficiency. However, the Chinese medicine composition cannot be used for patients with phlegm-blocking coronary heart disease and cannot be used for patients with other types of coronary heart disease. Therefore, the therapeutic effect and application scope need to be further improved. Summary of the invention

[0006] The purpose of the present invention is to provide an Astragalus Chinese medicine composition for treating coronary heart disease, which has multiple effects such as promoting blood circulation and removing blood stasis, removing phlegm and removing dampness, lowering blood lipids and blood pressure, and can treat coronary heart disease caused by heart vessel obstruction, phlegm and dampness accumulation and hyperlipidemia. The Chinese medicine of the present invention not only conforms to the basic theory of traditional Chinese medicine, but also combines with modern research. The combination of various medicines can treat both the symptoms and the root causes, and the effect is good.

[0007] The first purpose of the present invention is to provide an Astragalus Chinese medicine composition for treating coronary heart disease, which is composed of the following Chinese medicine composition: 144g of Astragalus, 108g of Pueraria, 108g of Cassia seed, 108g of Poria, 48g of Mistletoe, 36g of Chuanxiong, and 48g of Panax notoginseng.

[0008] The second object of the present invention is to provide a method for preparing the above-mentioned pharmaceutical composition, comprising the following steps:

[0009] Take 18g of Chuanxiong and 48g of Panax notoginseng and grind them into fine powder; extract Pueraria root with 85% ethanol for three times by heating and refluxing, combine the extracts, and recover the ethanol by decompressing the filtrate; extract Cassia seed and Poria with ethanol by heating and refluxing once, and recover the ethanol by decompressing the filtrate; the remaining Astragalus, Mistletoe, and 18g of Chuanxiong are decocted three times with the residues after alcohol extraction of the above-mentioned Pueraria root, Cassia seed, and Poria, and the filtrates are combined and concentrated, and combined with the above-mentioned alcohol extraction concentrate, and concentrated to 80°C to obtain a clear paste with a relative density of 1.20, add Chuanxiong and Panax notoginseng fine powder and appropriate amounts of powdered sugar and dextrin, mix well, granulate with ethanol, dry, and granulate to make 1000g, that is, granules.

[0010] The third object of the present invention is to provide the use of the above-mentioned pharmaceutical composition in the preparation of a drug for treating coronary heart disease caused by heart vessel obstruction, phlegm and dampness accumulation, and hyperlipidemia.

[0011] Compared with the prior art, the present invention has at least the following beneficial effects:

[0012] (1) In the Chinese medicine composition of the present invention, astragalus is used as the main drug to comprehensively improve heart function and strengthen the circulation of qi and blood; kudzu root, cassia seed and poria are used as auxiliary drugs to synergistically enhance myocardial blood supply, regulate blood lipids and prevent atherosclerosis; mistletoe is used as an adjuvant to regulate the spleen and stomach, promote dampness and lower blood pressure, and reduce the burden on the heart; chuanxiong and panax notoginseng are used as guiding drugs to guide other drugs to exert the effect of promoting blood circulation and removing blood stasis, thereby ensuring smooth blood flow in the coronary artery; through the interaction of the above drugs, it has the effects of improving blood circulation, regulating blood lipids and preventing blood stasis; that is, the Chinese medicine composition can effectively treat coronary heart disease through multi-level and multi-faceted conditioning, and is particularly suitable for patients with coronary heart disease accompanied by multiple complex symptoms such as hyperlipidemia, heart vessel obstruction, phlegm and dampness obstruction.

[0013] (2) The liver-clearing and liver-pacifying effects of Cassia seed help regulate blood lipids, and combined with the yang-raising effect of Pueraria root, it can improve the function of the cardiovascular system. The combination of the two can promote blood circulation and help alleviate symptoms related to coronary heart disease; at the same time, the effect of Cassia seed in moistening the intestines and relieving constipation can assist the effect of Poria cocos in promoting diuresis and strengthening the spleen, effectively helping to expel excess moisture and toxins from the body, further improving metabolism, and regulating blood lipid levels; in the Chinese medicine composition of the present invention, the auxiliary drugs Pueraria root, Cassia seed and Poria cocos have the effects of synergistically reducing the blood rheology of blood stasis rats, synergistically inhibiting thrombosis, and synergistically lowering blood lipids. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 Effects of Chinese herbal medicine composition AD on blood rheology in rats with blood stasis;

[0015] Figure 2 Effects of Chinese herbal medicine composition AD on thrombosis in rats;

[0016] Figure 3 Effect of the Chinese medicine composition AD on blood lipid metabolism in rats with coronary heart disease. DETAILED DESCRIPTION

[0017] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.

[0018] Example 1 Preparation of Chinese medicine composition:

[0019] Group A: According to CN 115282195 Patent B records a weight ratio of: 144g of Astragalus, 108g of Pueraria, 108g of Salvia miltiorrhiza, 48g of Mistletoe, 108g of Hawthorn, 36g of Chuanxiong, and 48g of Panax notoginseng. Its preparation method is: take 18g of Chuanxiong and 48g of Panax notoginseng and grind them into fine powder; Pueraria is heated and refluxed with 85% ethanol for extraction three times, the extracts are combined, and the filtrate is decompressed to recover ethanol; Hawthorn and Salvia miltiorrhiza are heated and refluxed with ethanol once, and the filtrate is decompressed to recover ethanol, and the remaining Astragalus, Mistletoe, and Chuanxiong 18g are boiled three times together with the residues after the above-mentioned Hawthorn and Salvia miltiorrhiza alcohol extraction, the filtrates are combined and concentrated, and combined with the above-mentioned alcohol extraction concentrate, and when concentrated to 80°C, a clear paste with a relative density of 1.30 is measured, and Chuanxiong and Panax notoginseng fine powder and appropriate amounts of powdered sugar and dextrin are added to mix, granulated with ethanol, dried, and granulated to 1000g, that is, granules are obtained.

[0020] Group B: It is composed of 144g of Astragalus, 108g of Pueraria, 100g of Poria, 48g of Mistletoe, 36g of Chuanxiong and 48g of Panax notoginseng. Its preparation method is as follows: 18g of Chuanxiong and 48g of Panax notoginseng are crushed into fine powder; Pueraria is heated and refluxed for extraction three times with 85% ethanol, the extracts are combined, and the filtrate is decompressed to recover ethanol; Poria is heated and refluxed for extraction once with ethanol, and the filtrate is decompressed to recover ethanol, and the remaining Astragalus, Mistletoe and Chuanxiong 18g are decocted three times with water together with the residues after alcohol extraction of the above Pueraria and Poria, the filtrates are combined, concentrated, and combined with the above alcohol extraction concentrate, and when concentrated to 80°C, a clear paste with a relative density of 1.15 is obtained, and Chuanxiong and Panax notoginseng fine powder and appropriate amounts of powdered sugar and dextrin are added to mix, granulated with ethanol, dried, and granulated to 1000g, thereby obtaining granules.

[0021] Group C: composed of 144g of Astragalus, 108g of Pueraria, 108g of Cassia, 48g of Mistletoe, 36g of Chuanxiong and 48g of Panax notoginseng. 18g of Chuanxiong and 48g of Panax notoginseng were crushed into fine powder; Pueraria was extracted with 85% ethanol for three times by heating and refluxing, the extracts were combined, and the filtrate was decompressed to recover ethanol; Cassia was extracted with ethanol for one time by heating and refluxing, and the filtrate was decompressed to recover ethanol; the remaining Astragalus, Mistletoe and Chuanxiong 18g were decocted three times with water together with the residues after alcohol extraction of the above Pueraria and Cassia, the filtrates were combined and concentrated, and combined with the above alcohol extraction concentrate, and a clear paste with a relative density of 1.10 was obtained when it was concentrated to 80°C, and Chuanxiong and Panax notoginseng fine powder and appropriate amounts of powdered sugar and dextrin were added to mix, granulated with ethanol, dried, and granulated to 1000g, that is, granules were obtained.

[0022] Group D: It is composed of 144g of Astragalus, 108g of Pueraria, 108g of Cassia, 108g of Poria, 48g of Mistletoe, 36g of Chuanxiong and 48g of Panax notoginseng. Its preparation method is as follows: 18g of Chuanxiong and 48g of Panax notoginseng are crushed into fine powder; Pueraria is heated and refluxed for extraction three times with 85% ethanol, the extracts are combined, and the filtrate is decompressed to recover ethanol; Cassia and Poria are heated and refluxed for extraction once with ethanol, and the filtrate is decompressed to recover ethanol; the remaining Astragalus, Mistletoe and Chuanxiong 18g are decocted three times with water together with the residues after alcohol extraction of the above-mentioned Pueraria, Cassia and Poria, the filtrates are combined and concentrated, and combined with the above-mentioned alcohol extraction concentrate, and when concentrated to 80°C, a clear paste with a relative density of 1.20 is obtained, and Chuanxiong and Panax notoginseng fine powders and appropriate amounts of powdered sugar and dextrin are added to mix evenly, granulated with ethanol, dried, and granulated to 1000g, thereby obtaining granules.

[0023] Example 2 Effect of Chinese medicine composition on blood rheology in rats with blood stasis

[0024] Fifty Wistar rats, half male and half female, weighing 200-240g, were randomly divided into 5 groups, 10 rats in each group. The control group was gavaged with the same volume of normal saline; Groups A, B, C, and D were gavaged with 3.6g of crude drug / kg. The drug was administered continuously for 7 days, once a day; 1 hour after the last administration, rats in each group were subcutaneously injected with epinephrine hydrochloride 0.08ml / 10g (10μg / m1), twice, with an interval of 4h. Between the two injections of epinephrine hydrochloride, the rats were immersed in ice water for 5min to form a blood stasis model. After treatment, rats in each group were fasted but not watered. Blood was collected the next morning and placed in a centrifuge tube containing a small amount of sodium heparin. The whole blood viscosity and plasma viscosity were measured using a blood viscosity meter. The results are shown in the figure. Figure 1 .

[0025] Figure 1 The results showed that group A, group B, group C and group D could significantly reduce the whole blood viscosity and plasma viscosity, and group D had a very significant difference compared with the control group (P < 0.01); the effect of group D in reducing the whole blood viscosity and plasma viscosity was much better than that of group A, group B and group C, among which the reducing activity of group A and group B was significantly different from that of group C (P < 0.05), while there was no significant difference between group A and group B; the analysis showed that in the above-mentioned Chinese medicine formula, the ministerial drugs Pueraria root, Cassia seed and Poria cocos had a synergistic effect of reducing the blood rheology of blood stasis rats;

[0026] Example 3 Effect of Chinese medicine composition on thrombosis in rats

[0027] Fifty Wistar rats, half male and half female, weighing 200-240g, were randomly divided into 5 groups, 10 in each group. The control group was gavaged with the same volume of saline; groups A, B, C, and D were gavaged with 3.6g of crude drug / kg. The drugs were given continuously for 7 days, once a day; 1 hour after the last administration, 50mg / kg of sodium pentobarbital was injected intraperitoneally for anesthesia, and the trachea was intubated. The two ends of a polyethylene tube with a 5cm long middle thread (No. 4 surgical thread) and filled with 50u / ml of heparinized saline were inserted into the pre-isolated right common carotid artery and left external jugular vein to form an arteriovenous blood flow bypass. Then, 50u / kg of heparinized saline was injected through the femoral vein of the rat to open the blood flow. After 15 minutes, the blood flow was blocked, and the thrombus was quickly removed and weighed. The total weight minus the weight of the silk thread was the wet weight of the thrombus. The results are shown in the figure. Figure 2 .

[0028] Figure 2 The results showed that group A, group B, group C and group D could significantly reduce the weight of platelet thrombus in arteriovenous bypass of rats, and group D had a very significant difference compared with the control group (P < 0.01); the effect of group D in inhibiting thrombosis was much better than that of group A, group B and group C. It can be seen that in the above Chinese medicine formula, the auxiliary drugs Pueraria root, Cassia seed and Poria cocos have a synergistic effect in inhibiting thrombosis;

[0029] Example 4 Effect of Chinese medicine composition on blood lipid metabolism in rats with coronary heart disease

[0030] After 40 SPF-grade C57BL / 6 mice (weight 20±2g) were fed for 1 week to adapt to the experimental environment, 8 mice were randomly selected as the control group and fed with ordinary feed until the end of the experiment; the remaining mice were fed with high-fat feed (10% casein, 2% cholesterol, 10% lard, 0.2% propylthiouracil, 0.5% sodium cholate and 77.3% ordinary feed) for a total of 10 weeks; in addition to the high-fat diet, posterior pituitary hormone (30U / kg) was injected intraperitoneally for 3 days to prepare the CHD model. The 24 successfully prepared CHD mice were randomly divided into 4 groups. Group A, Group B, Group C, and Group D were gavaged with 3.6g crude drug / kg respectively, and the drug was administered once a day for 7 consecutive days. After 3 weeks, blood was collected from the inner canthus of all mice, and the levels of total cholesterol (TCHO), high-density lipoprotein (HDL), low-density lipoprotein cholesterol (LDL), and triglyceride (TG) were measured using a blood liquid biochemical analyzer. The results are shown in the figure. Figure 3 .

[0031] Figure 3 The results showed that compared with the Control group, the TG, T-CHO, HDL-C and LDL-C levels in the CHD group were significantly increased, indicating that the modeling was successful. Among them, Group A, Group B, Group C and Group D could significantly reduce the levels of TG, T-CHO, HDL-C and LDL-C in the blood, and the lipid-lowering effect of Group D was the most significant. It can be seen that in the above-mentioned Chinese medicine formula, the auxiliary drugs Pueraria lobata, Cassia seed and Poria cocos have a synergistic lipid-lowering effect.

[0032] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A Chinese herbal composition of Astragalus for treating coronary heart disease caused by heart blockage, phlegm-dampness accumulation and hyperlipidemia, characterized in that: The Chinese medicine composition is composed of the following Chinese medicines: 144g of Astragalus, 108g of Pueraria, 108g of Cassia seed, 108g of Poria, 48g of Mistletoe, 36g of Chuanxiong, and 48g of Panax notoginseng. The preparation method of the Chinese medicine composition comprises the following steps: 18g of Chuanxiong and 48g of Panax notoginseng are crushed into fine powder; Pueraria is heated and refluxed with 85% ethanol for three times, the extracts are combined, and the filtrate is decompressed to recover ethanol; Cassia seed and Poria are heated and refluxed with ethanol Reflux extraction was performed once, and the filtrate was decompressed to recover ethanol. The remaining astragalus, mistletoe, and 18g of Chuanxiong were decocted three times together with the residue after alcohol extraction of Pueraria lobata, Cassia seed, and Poria cocos. The filtrates were combined, concentrated, and combined with the above alcohol-extracted concentrated solution. When concentrated to 80°C, a clear paste with a relative density of 1.20 was obtained. Chuanxiong, Panax notoginseng fine powder, and appropriate amounts of powdered sugar and dextrin were added and mixed. The mixture was granulated with ethanol, dried, and granulated to 1000g to obtain granules.

2. Use of the Astragalus Chinese medicine composition according to claim 1 in the preparation of a medicament for treating coronary heart disease caused by heart vessel obstruction, phlegm-damp accumulation and hyperlipidemia.

Images